DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

EW·Edwards Lifesciences Corporation

$.
+. (+.%)
After Hours
High
$87.83
Open
$86.96
Market Cap
50.30B
52W High
$89.60
Low
$86.52
P. Close
$87.36
P/E
45.89
52W Low
$72.30
Fwd P/E
25.94
DailyIQ Est.
$99.24
Technical Score (1D)
82
BUY
News Sentiment
76
BULLISH
CMS has proposed expanding Medicare reimbursement for transcatheter aortic valve replacement (TAVR), a change that is expected to lift demand for Edwards Lifesciences’ transcatheter valves. RBC analysts project a revenue boost tied to the expanded coverage and maintain an Outperform rating with a $100 price target. The rule’s final implementation date is the next critical event, as it will determine when increased procedure volumes begin to materialize. EW’s recent earnings already show strong TAVR revenue growth, suggesting the company is positioned to capture the upside from the coverage change. Traders should monitor EW’s quarterly TAVR volume reports for early signs of the rule’s impact. In the short term, the expanded coverage could translate into higher utilization rates, potentially tightening the competitive advantage over Medtronic and Boston Scientific. Macro headwinds and currency volatility remain a risk, as they could temper growth even if procedure volumes rise. Watch for the CMS decision announcement and any adjustments to reimbursement rates that could alter the projected lift. Keep an eye on EW’s upcoming earnings release for confirmation of TAVR volume growth and any commentary on the rule’s effect.
Earnings Summary
Edwards Lifesciences (EW) is a global medical‑technology company that designs and markets transcatheter heart‑valve solutions, including the SAPIEN, PASCAL PRECISION, and Cardioband platforms, and surgical valves such as INSPIRIS and MITRIS RESILIA, serving patients in the United States, Europe, Japan and beyond. In the highly competitive cardiovascular‑devices sector, the firm’s focus on minimally invasive aortic, mitral and tricuspid valve therapies positions it as a leader in a market driven by aging populations and expanding procedural indications. In the most recent two quarters, EW reported revenue of $1.5696 billion in Q4 2025 and $1.6486 billion in Q1 2026, up 13.8 % and 16.8 % YoY respectively, while EPS rose from $0.58 to $0.78, a 21 % increase; the company beat revenue estimates in both periods and earned a $0.78 EPS versus a $0.749 estimate in Q1 2026, but missed the $0.69034 EPS estimate in Q4 2025. Compared with the prior two quarters (Q3 2025 $1.5531 billion, $0.67 EPS; Q2 2025 $1.5322 billion, $0.67 EPS), revenue has accelerated and EPS has improved, with the firm achieving a 2‑out‑of‑3 quarter earnings‑beat streak. Historically, EW has posted double‑digit revenue growth year over year, with the latest quarter showing a 13.8 % YoY increase, while EPS has fluctuated, reflecting the impact of one‑off charges and currency swings; nevertheless, the company has consistently outperformed revenue estimates across the last four quarters. Recent news highlights a CMS proposal to expand Medicare reimbursement for transcatheter aortic valve replacement, a change that could lift TAVR volumes and strengthen EW’s competitive position; analysts note that the rule’s implementation date will be a key event, and that macro headwinds and currency volatility could temper the upside. Investors should watch for the CMS decision announcement, quarterly TAVR volume reports, currency movements in the euro and yen, and any guidance updates from the newly appointed CFO, as these factors will shape the next earnings cycle.

EPS

EstBeatMiss
$0.55$0.61$0.68$0.74$0.81Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$0.74 - -
Q1'26$0.75$0.78+4.1%
Q4'25$0.69$0.58-16.0%
Q3'25$0.59$0.67+12.6%
Q2'25$0.62$0.67+7.6%
Q1'25$0.60$0.64+7.5%

Revenue

EstBeatMiss
$1.4B$1.5B$1.6B$1.7B$1.8BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.8B - -
Q1'26$1.6B$1.6B+0.3%
Q4'25$1.6B$1.6B+0.2%
Q3'25 - $1.6B -
Q2'25 - $1.5B -
Q1'25 - $1.4B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

EW Stock Snapshot

EW is currently trading at $87.35, giving Edwards Lifesciences Corporation a market cap of 50.30B and a P/E ratio of 45.9. Today's range spans $86.52–$87.83, with shares opening at $86.96 and moving down $0.01 (0.0%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 76/100.

Over the past year EW has traded between $72.30 and $89.60 - the current price is +20.8% off the 52-week low and -2.5% from the high. 44 analysts cover the stock with a Buy consensus and a mean 12-month target of $96.92 (range $84.00–$110.00), implying upside of +11.0%.

The breakout geometry on EW is constructive - price at $87.35 (in the upper portion of its 52-week range in $72.30–$89.60), scoring 82/100 (BUY) with bullish sentiment (76/100). (P/E: 45.9) At 50.30B in Healthcare market cap, technical breakouts through prior resistance at this capitalization tier tend to be better validated than in smaller-cap peers - institutional participation means that cleared levels attract follow-through buying rather than immediate fade behavior.

The combination of a BUY signal (82/100) and bullish news sentiment (76/100) puts EW on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 50.30B in Healthcare market cap without immediately moving the stock. At $87.35 (in the upper portion of its 52-week range in the $72.30–$89.60 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.